Good evening. This snapshot of stories and roundup is recommended just for you, based on your interests and reading history. | | | | Todd Engel, at home in Columbia, Maryland, is among thousands of patients suing Novo Nordisk and Eli Lilly over their GLP-1 drugs. (Pete Kiehart/For The Washington Post) | | | | | | | What to know Todd Engel, legally blind, alleges in a lawsuit that Novo Nordisk's Ozempic caused his vision loss. Thousands are suing over GLP-1 drugs' risks. While effective for many, rare complications like gastrointestinal issues and vision loss are under scrutiny. Novo Nordisk and Eli Lilly maintain their drugs are safe. Summary is AI-generated, newsroom-reviewed. | | | | | How was today's newsletter? | | | | | | | | |